Uricase and other novel agents for the management of patients with treatment-failure gout

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current Rheumatology Reports

• Publication date

  2007-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11926-007-0041-YPMID 17531181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

  2008cited by this paper
• Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

  2007cited by this paper
• Febuxostat Compared with Allopurinol in Patients With Hyperuricemia and Gout

  2007cited by this paper
• Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study.

  2006cited by this paper
• Human parvovirus B19 viraemia is associated with neither IgM positivity nor anaemia in patients with rheumatic diseases

  2006cited by this paper
• Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

  2006cited by this paper
• Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.

  2006cited by this paper
• Rasburicase treatment in severe tophaceous gout: a novel therapeutic option

  2006cited by this paper
• Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol

  2006cited by this paper
• The management of gout at an academic healthcare center in Beijing: a physician survey.

  2006cited by this paper
• Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.

  2006cited by this paper
• IL1RN genotype as a risk factor for joint pain in hereditary haemochromatosis?

  2006cited by this paper
• Serum Urate Levels and Gout Flares: Analysis From Managed Care Data

  2006cited by this paper
• Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?

  2005cited by this paper
• Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

  2005cited by this paper
• Urate oxidase (rasburicase) for treatment of severe tophaceous gout.

  2005cited by this paper
• Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project.

  2005cited by this paper
• Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

  2005cited by this paper
• Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

  2005cited by this paper
• Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

  2005cited by this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cited by this paper
• Quality of care indicators for gout management.

  2004cited by this paper
• Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers

  2004cited by this paper
• Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.

  2004cited by this paper
• Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout.

  2003cited by this paper
• Winners of the 2005 American College of Rheumatology Annual Slide Competition.

  2002cited by this paper
• Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

  2002cited by this paper
• Relation between adverse events associated with allopurinol and renal function in patients with gout

  2001cited by this paper
• Quality use of allopurinol in the elderly.

  2000cited by this paper
• How is Gout Managed in Primary Care? A Review of Current Practice and Proposed Guidelines

  2000cited by this paper
• J Am Soc Nephrol 12: 1001–1009, 2001 Diabetes Insipidus in Uricase-Deficient Mice: A Model for Evaluating Therapy with Poly(Ethylene Glycol)-Modified

  2000cited by this paper
• Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.

  1995cited by this paper
• Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.

  1994cited by this paper
• Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.

  1988cited by this paper
• Polyarticular Versus Monoarticular Gout: A Prospective, Comparative Analysis of Clinical Features

  1988cited by this paper
• POLYARTICULAR VERSUS MONOARTICULAR GOUT.

  1988cited by this paper
• A Report of Three Cases

  1986cited by this paper
• Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

  1984influential reference
• Hypouricaemic effect of polyethyleneglycol modified urate oxidase.

  1981cited by this paper
• Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.

  1981cited by this paper
• Letter: False-positive acid-fast smears.

  1975cited by this paper
• Arthritis and allied conditions;: A textbook of rheumatology

  1972cited by this paper

• Mitigating Uricase Immunogenicity through Zwitterionic Peptide Fusion for Enhanced Gout Therapy.

  2025cites this paper
• Priestia megaterium ASC-1 Isolated from Pickled Cabbage Ameliorates Hyperuricemia by Degrading Uric Acid in Rats

  2024cites this paper
• Dissecting Uricase Immunogenicity: Unveiling the Role of Quaternary Epitopes through In Silico Analysis

  2024cites this paper
• Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

  2023influential citation
• Probiotic Limosilactobacillus fermentum GR-3 ameliorates human hyperuricemia via degrading and promoting excretion of uric acid

  2022cites this paper
• A systematic review on the prevalence, pathophysiology, diagnosis, management and treatment of gout (2007-2018)

  2018cites this paper
• Serum Uric Acid Levels as an Indicator for Metabolically Unhealthy Obesity in Children and Adolescents

  2018cites this paper
• CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population.

  2017cites this paper
• Urate Oxidase produced by Lucilia sericata medical maggots is localized in Malpighian tubes and facilitates allantoin production.

  2017cites this paper
• Isolation and Characterization of Xanthine Oxidase Inhibitor(s) from Endophytic Fungi

  2017cites this paper
• Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model.

  2016cites this paper
• Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.

  2016cites this paper
• Epidermal growth factor gene is a newly identified candidate gene for gout

  2016cites this paper
• Correlation of GLUT9 Polymorphisms With Gout Risk

  2015cites this paper
• The CC chemokine ligand 2 (CCL2) polymorphism −2518A/G is associated with gout in the Chinese Han male population

  2015cites this paper
• Analysis of patents on anti-gout therapies issued in China

  2014cites this paper
• Treatment of Hyperuricemia in Gout

  2014cites this paper
• Transcoronary septal ablation in hypertrophic obstructive cardiomyopathy by embolizing microspheres.

  2013cites this paper
• Reengineering a human-like uricase for the treatment of gout

  2013cites this paper
• Trp64Arg (rs4994) polymorphism of β3-adrenergic receptor gene is associated with hyperuricemia in a Chinese male population

  2013cites this paper
• PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation

  2013cites this paper
• A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.

  2013cites this paper
• Recent advances in management of gout.

  2012cites this paper
• Dna moczanowa — antyczna choroba wciąż problematyczna w XXI wieku

  2012cites this paper
• Pegloticase: A Novel Agent for Treatment-Refractory Gout

  2012cites this paper
• Effects of Reaction Conditions on Interactions of Some Purine Derivatives with the Intracellular Uricase from Bacillus fastidiosus *: Effects of Reaction Conditions on Interactions of Some Purine Derivatives with the Intracellular Uricase from Bacillus fastidiosus *

  2011cites this paper
• Genetic association of polymorphism rs1333049 with gout.

  2011cites this paper
• Febuxostat efficacy in allopurinol-resistant tophaceous gout.

  2011cites this paper
• The management of gout and hyperuricemia

  2011cites this paper
• Update on gout: new therapeutic strategies and options

  2010cites this paper
• A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia

  2010cites this paper
• Febuxostat provides new gout treatment option.

  2010cites this paper
• Novel Risk Factors for Type II Diabetes Mellitus and Coronary Heart Disease

  2010cites this paper
• Effects of Modification of Amino Groups with Poly(Ethylene Glycol) on a Recombinant Uricase from Bacillus fastidiosus

  2010cites this paper
• Quality of Life and Disability in Patients with Treatment-Failure Gout

  2009cites this paper
• Reversible Inactivation of an Intracellular Uricase from Bacillus fastidiosus via Dissociation of Homotetramer into Homodimers in Solutions of Low Ionic Strength

  2009cites this paper
• Gout. Novel therapies for treatment of gout and hyperuricemia

  2009cites this paper
• Treatment failure gout.

  2009cites this paper
• Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout

  2009cites this paper
• Reassessing serum urate targets in the management of refractory gout: can you go too low?

  2009cites this paper
• Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.

  2008cites this paper
• Serum uric acid and metabolic risk factors in three ethnic groups: Asian Indians and Creoles in Mauritius and Chinese in Qingdao, China

  2008cites this paper
• Refractory gout: what is it and what to do about it?

  2008cites this paper
• We can make gout management more successful now

  2008cites this paper
• Gota en el anciano

  2008cites this paper
• PEG-uricase in the management of treatment-resistant gout and hyperuricemia.

  2008cites this paper
• The Good Neighbor Alliance

  2008cites this paper
• Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

  2008cites this paper
• Gout management: let's get it right this time.

  2008cites this paper
• Learning how and when to employ uricase as bridge therapy in refractory gout.

  2007influential citation
• Original Contribution Racial Differences in Gout Incidence in a Population-based Cohort: Atherosclerosis Risk in Communities Study

  year unknowncites this paper